Praxbind Adverse Reactions



Boehringer Ingelheim


Zuellig Pharma
Full Prescribing Info
Adverse Reactions
The safety of Praxbind has been evaluated in 224 healthy subjects as well as 123 patients in an ongoing phase III trial, who had uncontrolled bleeding or required emergency surgery or procedures and were under treatment with Pradaxa (dabigatran etexilate).
No adverse reactions have been identified.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in